- Home
- CHEC vs SCLX Comparison
CHEC vs SCLX Comparison
Compare CHEC & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHEC | SCLX |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.7M | 139.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHEC | SCLX |
|---|---|---|
| Price | $9.97 | $16.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 93.4K | ★ 120.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.91 | $3.60 |
| 52 Week High | $10.56 | $34.27 |
Technical Indicators
Market Signals| Indicator | CHEC | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.66 |
| Support Level | N/A | $18.34 |
| Resistance Level | N/A | $20.62 |
| Average True Range (ATR) | 0.00 | 1.46 |
| MACD | 0.00 | -0.39 |
| Stochastic Oscillator | 0.00 | 3.10 |
Price Performance
Historical ComparisonAbout CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.